Program
Dexmedetomidine
Also written as “BXCL501”, “Intranasal Dexmedetomidine” and “Dexmedetomidine hydrochloride”.
Its studies are mostly in Psychomotor Agitation · Delirium · Schizophrenia · Bipolar Disorder · Dementia, led by 8 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 160 open or running | phase 4since Aug 31, 2005 | Aug 31, 2005 | none ahead |
| BioXcel Therapeutics | 131 open or running | phase 4since Sep 11, 2023 | Jul 3, 2019 | Jul 31, 2027phase 1 · NCT05025605 |
| Orion Corporation, Orion Pharma | 50 open or running | phase 4since Nov 9, 2018 | Sep 23, 2005 | none ahead |
| Jiangsu HengRui Medicine | 40 open or running | phase 3since May 6, 2020 | Aug 23, 2017 | none ahead |
| Baudax Bio | 20 open or running | phase 2since Jun 17, 2014 | Jun 17, 2014 | none ahead |
| Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology | 21 open or running | no phasesince Jul 11, 2023 | Jul 11, 2023 | none ahead |
| Egymedicalpedia | 21 open or running | early phase 1since Apr 8, 2023 | Apr 8, 2023 | none ahead |
| Teikoku Pharma USA | 10 open or running | phase 1since Sep 7, 2026 | Sep 7, 2026 | none ahead |
Also a collaborator on its studies: cognitive-research-corporation, propharma-group and maruishi-pharmaceutical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 30 studies since Aug 31, 2005.
- Jul 1, 2020Phase 2 study in Opioid-Related DisordersBioXcel Therapeutics · NCT04470050 · 225 enrolled · United States
- Mar 31, 2021Phase 2 study in Psychomotor AgitationBioXcel Therapeutics · NCT05313386 · United States
- Aug 24, 2021Phase 1 study in SchizophreniaBioXcel Therapeutics · NCT05025605 · 140 planned · United States
- Oct 20, 2021Phase 3 study in Preoperative Sedation of ChildrenJiangsu HengRui Medicine · NCT05111431 · 159 enrolled · China
- Feb 28, 2022Phase 2 study in Psychomotor AgitationBioXcel Therapeutics · NCT05276830 · 5 enrolled · United States
- Feb 28, 2022Phase 3 study in Psychomotor AgitationBioXcel Therapeutics · NCT05271552 · 151 enrolled · United States
- Dec 12, 20222 phase 3 studies in Psychomotor AgitationBioXcel Therapeutics · NCT05658510, NCT05665088
- Apr 8, 2023Egymedicalpedia's first study: early phase 1 study in Endoscopic Sinus SurgeryNew to EgymedicalpediaEgymedicalpedia · NCT05829148 · 120 enrolled · Egypt
- Jul 11, 2023Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology's first study: no phase study in Emergence DeliriumNew to Boston Intelligent Medical Research Center, Shenzhen United Scheme TechnologyBoston Intelligent Medical Research Center, Shenzhen United Scheme Technology · NCT05952050 · 120 planned · China
- Sep 11, 2023Phase 4 study in Bipolar DisorderBioXcel Therapeutics · NCT06041646 · 29 enrolled · United States
- Apr 22, 2024No phase study in Delirium in Old AgeBoston Intelligent Medical Research Center, Shenzhen United Scheme Technology · NCT06382961 · 287 enrolled · China
- Jun 9, 2024No phase study in Valvular Cardiac SurgeriesEgymedicalpedia · NCT06464263 · 60 planned · Egypt
- Jul 7, 2025Phase 2 study in Bipolar DisorderBioXcel Therapeutics · NCT07116694 · 33 enrolled · United States
- Sep 7, 2026Teikoku Pharma USA's first study: phase 1 study in Healthy SubjectsNew to Teikoku Pharma USATeikoku Pharma USA · NCT07818330 · 8 enrolled · Australia
Ahead
- Jul 31, 2027Primary completion: phase 1 study in SchizophreniaBioXcel Therapeutics · NCT05025605
TargetBeta
“Adrenergic receptor alpha-2 agonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| brimonidinerule | AbbVie | phase 4 | 54 |
| Oxymetazolinerule | AbbVie | phase 4 | 20 |
| Phentolaminerule | opus-genetics-inc | phase 4 | 18 |
| Epinephrinerule | nasus-pharma | phase 4 | 17 |
| tizanidinerule | Teva Pharmaceutical Industries | phase 4 | 11 |
| Clonidinerule | pharmafina | phase 4 | 5 |
| lofexidinerule | uswm-llc-dba-us-worldmeds | phase 3 | 15 |
Studies
All 45 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07818330Healthy Subjects · Australia | 1 | Terminated | Teikoku Pharma USA | Oct 30, 2026 | 8 |
| NCT07116694Bipolar Disorder · United States | 2 | Completed | BioXcel Therapeutics | Oct 7, 2025 | 33 |
| NCT06464263Valvular Cardiac Surgeries · Egypt | – | Recruiting | Egymedicalpedia | Feb 1, 2026 | 60 |
| NCT06382961Delirium in Old Age · China | – | Completed | Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology | Mar 6, 2024 | 287 |
| NCT06041646Bipolar Disorder · United States | 4 | Completed | BioXcel Therapeutics | Apr 29, 2024 | 29 |
| NCT05952050Emergence Delirium · China | – | Recruiting | Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology | Aug 1, 2023 | 120 |
| NCT05829148Endoscopic Sinus Surgery · Egypt | Early 1 | UNKNOWN | Egymedicalpedia | Nov 1, 2024 | 120 |
| NCT05665088Psychomotor Agitation · United States | 3 | Terminated | BioXcel Therapeutics | Sep 11, 2023 | 13 |
| NCT05658510Psychomotor Agitation · United States | 3 | Completed | BioXcel Therapeutics | Aug 15, 2025 | 452 |
| NCT05276830Psychomotor Agitation · United States | 2 | Terminated | BioXcel Therapeutics | Apr 1, 2022 | 5 |
| NCT05271552Psychomotor Agitation · United States | 3 | Completed | BioXcel Therapeutics | Apr 21, 2023 | 151 |
| NCT05111431Preoperative Sedation of Children · China | 3 | Completed | Jiangsu HengRui Medicine | May 20, 2022 | 159 |
| NCT05025605Schizophrenia · United States | 1 | Recruiting | BioXcel Therapeutics | Jul 31, 2027 | 140 |
| NCT05313386Psychomotor Agitation · United States | 2 | Withdrawn | BioXcel Therapeutics | Feb 21, 2022 | 0 |
| NCT04470050Opioid-Related Disorders · United States | 2 | Completed | BioXcel Therapeutics | Feb 18, 2021 | 225 |
| NCT04383418Preoperative Sedation · China | 3 | Completed | Jiangsu HengRui Medicine | Jun 2, 2021 | 309 |
| NCT04276883Psychomotor Agitation · United States | 3 | Completed | BioXcel Therapeutics | May 21, 2020 | 380 |
| NCT04268303Psychomotor Agitation · United States | 3 | Completed | BioXcel Therapeutics | May 6, 2020 | 380 |
| NCT04251910Psychomotor Agitation · United States | 2 | Completed | BioXcel Therapeutics | Jan 24, 2022 | 100 |
| NCT04237792MRI Sedation · United States, Japan | 4 | Completed | Pfizer | Nov 2, 2021 | 128 |
| NCT04200235Preoperative Sedation · China | 1 | Completed | Jiangsu HengRui Medicine | Aug 6, 2020 | 48 |
| NCT04010305Psychomotor Agitation · United States | 1 | Completed | BioXcel Therapeutics | Jul 31, 2019 | 135 |
| NCT03813277ICU Sedation · Russia | 4 | Completed | Orion Corporation, Orion Pharma | May 21, 2018 | 60 |
| NCT03293277Sedation · China | 1 | UNKNOWN | Jiangsu HengRui Medicine | Jul 2018 | 48 |
| NCT02757625ICU Sedation · Japan | 3 | Completed | Pfizer | May 24, 2017 | 63 |
| NCT02284243Pain, Postoperative · United States | 2 | Completed | Baudax Bio | Jun 2015 | 168 |
| NCT02169336Pain, Postoperative · United States | 2 | Terminated | Baudax Bio | Sep 2014 | 95 |
| NCT01519167Ultrasound · United States, Puerto Rico | 4 | Completed | Pfizer | Jan 2014 | 91 |
| NCT01508455Anesthesia · United States | 3 | Completed | Pfizer | May 2012 | 6 |
| NCT01438957Sedation · Japan | 3 | Completed | Pfizer | Nov 18, 2011 | 119 |
| NCT01378988Pain · United States | 2 | Completed | Pfizer | Aug 2011 | 5 |
| NCT01159262Sedation · United States, Guatemala | 3 | Completed | Pfizer | Aug 2011 | 36 |
| NCT00875550Sedation · United States, Canada | 3 | Completed | Pfizer | Jan 2011 | 175 |
| NCT00747721Pharmacokinetics · Finland | 1 | Completed | Orion Corporation, Orion Pharma | Jan 2009 | 13 |
| NCT00652028Intubated and Mechanically Ventilated Pediatric Subjects · United States, Guatemala | 2 | Completed | Pfizer | Apr 2010 | 69 |
| NCT00526760Sedation · Japan | 3 | Completed | Pfizer | Jun 2008 | 80 |
| NCT00481312Continuous Sedation in Initially Sedated Adults in ICU · Belgium, Estonia, Finland and more | 3 | Completed | Orion Corporation, Orion Pharma | Aug 2009 | 501 |
| NCT00479661Continuous Sedation in Initially Sedated Adults in ICU · Belgium, Finland, Germany and more | 3 | Completed | Orion Corporation, Orion Pharma | Mar 2010 | 500 |
| NCT00464763Delirium · United States | 3 | Withdrawn | Pfizer | 0 | |
| NCT00460473Delirium · United States | 3 | Terminated | Pfizer | Nov 2007 | 52 |
| NCT00398827Anesthesia · United States | 3 | Completed | Pfizer | 326 | |
| NCT00383890Awake Fiberoptic Intubation · United States | 3 | Completed | Pfizer | Jan 2007 | 124 |
| NCT00318955Conscious Sedation · Japan | 4 | Completed | Pfizer | Aug 2006 | 85 |
| NCT00226785Conscious Sedation · Finland, Switzerland | 3 | Terminated | Orion Corporation, Orion Pharma | 900 | |
| NCT00216190Mechanically Ventilated and Intubated Subjects · United States, Argentina, Australia and more | 4 | Completed | Pfizer | 420 |
How it is read
Names in the registry
- “Dexmedetomidine”, 20 entries
- “BXCL501”, 6 entries
- “Intranasal Dexmedetomidine”, 3 entries
- “Dexmedetomidine hydrochloride”, 2 entries
- “Dexmedetomidine HCL Injection”, 2 entries
Conditions, from the studies’ own filings
- Psychomotor Agitation, 4 studies
- Delirium, 4 studies
- Schizophrenia, 3 studies
- Bipolar Disorder, 2 studies
- Dementia, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.